---
title: A randomized phase III study of standard versus high-dose cytarabine with or
  without vorinostat for AML
date: '2023-11-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37935977/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231108170756&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'Prior experience indicated that use of higher doses of cytarabine during
  induction for acute myeloid leukemia (AML) with a histone deacetylase inhibitor
  resulted in high response rates. S1203 was a randomized multicenter trial for previously
  untreated patients aged 18-60 with AML which compared daunorubicin and cytarabine
  (DA), idarubicin with higher dose cytarabine (IA) and IA with vorinostat (IA + V).
  The primary endpoint was event free survival (EFS). 738 patients were randomized:
  261 to ...'
disable_comments: true
---
Prior experience indicated that use of higher doses of cytarabine during induction for acute myeloid leukemia (AML) with a histone deacetylase inhibitor resulted in high response rates. S1203 was a randomized multicenter trial for previously untreated patients aged 18-60 with AML which compared daunorubicin and cytarabine (DA), idarubicin with higher dose cytarabine (IA) and IA with vorinostat (IA + V). The primary endpoint was event free survival (EFS). 738 patients were randomized: 261 to ...